Timo Vesikari

20.2k total citations · 3 hit papers
272 papers, 12.3k citations indexed

About

Timo Vesikari is a scholar working on Infectious Diseases, Cardiology and Cardiovascular Medicine and Epidemiology. According to data from OpenAlex, Timo Vesikari has authored 272 papers receiving a total of 12.3k indexed citations (citations by other indexed papers that have themselves been cited), including 197 papers in Infectious Diseases, 102 papers in Cardiology and Cardiovascular Medicine and 83 papers in Epidemiology. Recurrent topics in Timo Vesikari's work include Viral gastroenteritis research and epidemiology (184 papers), Viral Infections and Immunology Research (102 papers) and Animal Virus Infections Studies (78 papers). Timo Vesikari is often cited by papers focused on Viral gastroenteritis research and epidemiology (184 papers), Viral Infections and Immunology Research (102 papers) and Animal Virus Infections Studies (78 papers). Timo Vesikari collaborates with scholars based in Finland, United States and Belgium. Timo Vesikari's co-authors include Tarja Ruuska, Aino Karvonen, Erika Isolauri, Vesna Blazevic, A. Delem, Suvi Lappalainen, Jaana Joensuu, Leena Huhti, Xiaoli Pang and Marjo Salminen and has published in prestigious journals such as New England Journal of Medicine, The Lancet and PLoS ONE.

In The Last Decade

Timo Vesikari

268 papers receiving 11.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Live Attenuated versus Inactivated Influenza Vaccine in Infants and Young Children

2007 611 citations Timo Vesikari et al. profile →
Rotavirus Disease in Finnish Children: Use of Numerical Scores for Clinical Severity of Diarrhoeal Episodes

1990 589 citations Timo Vesikari et al. profile →
Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study

2007 510 citations Timo Vesikari et al. The Lancet profile →

Peers

Countries citing papers authored by Timo Vesikari

Since Specialization

Citations

This map shows the geographic impact of Timo Vesikari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timo Vesikari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timo Vesikari more than expected).

Fields of papers citing papers by Timo Vesikari

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timo Vesikari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timo Vesikari. The network helps show where Timo Vesikari may publish in the future.

Co-authorship network of co-authors of Timo Vesikari

This figure shows the co-authorship network connecting the top 25 collaborators of Timo Vesikari. A scholar is included among the top collaborators of Timo Vesikari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Timo Vesikari. Timo Vesikari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	PreHevbrio: the first approved 3-antigen hepatitis B vaccine 2023 ·Expert Review of Vaccines ·Timo Vesikari, Joanne M. Langley, (unknown), Francisco Díaz‐Mitoma	9
2	The persistence of seroprotective levels of antibodies after vaccination with PreHevbrio, a 3-antigen hepatitis B vaccine 2023 ·Vaccine ·Timo Vesikari, Joanne M. Langley, Johanna N. Spaans, (unknown), (unknown), Bebi Yassin-Rajkumar, David E. Anderson, Francisco Díaz‐Mitoma	9
3	Human Protoparvovirus DNA and IgG in Children and Adults with and without Respiratory or Gastrointestinal Infections 2021 ·Viruses ·(unknown), (unknown), (unknown), Minna Paloniemi, Timo Vesikari, Maija Lappalainen, Eveliina Tarkka, Zaiga Nora-Krūkle, (unknown), Kim Vettenranta, Charles Mangani, (unknown), Yue‐Mei Fan, Per Ashorn, Elina Väisänen, Maria Söderlund‐Venermo	13
4	Rotavirus VP6 Adjuvant Effect on Norovirus GII.4 Virus‐Like Particle Uptake and Presentation by Bone Marrow‐Derived Dendritic Cells In Vitro and In Vivo 2020 ·Journal of Immunology Research ·Kirsi Tamminen, (unknown), Timo Vesikari, Vesna Blazevic	11
5	Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18–64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials 2020 ·The Lancet ·Brian J. Ward, А. И. Макарков, Annie Séguin, Stéphane Pillet, Sonia Trépanier, (unknown), Michael Libman, Timo Vesikari, Nathalie Landry	132
6	TIPICO IX: report of the 9^th interactive infectious disease workshop on infectious diseases and vaccines 2019 ·Human Vaccines & Immunotherapeutics ·Federico Martinón‐Torres, Xavier Bosch, Rino Rappuoli, Shamez Ladhani, (unknown), Timo Vesikari, Adolfo Garcı́a-Sastre, Irene Rivero‐Calle, José Gómez Rial, Antonio Salas, Carlos Martı́n, Adam Finn, Robb Butler	20
7	Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial 2018 ·The Lancet Respiratory Medicine ·Timo Vesikari, Judith L. Kirstein, (unknown), Brett Leav, (unknown), Leah Isakov, (unknown), Janine Oberyé, Esther Heijnen	47
8	Norovirus-specific mucosal antibodies correlate to systemic antibodies and block norovirus virus-like particles binding to histo-blood group antigens 2018 ·Clinical Immunology ·Kirsi Tamminen, Maria Malm, Timo Vesikari, Vesna Blazevic	13
9	Rotavirus Recombinant VP6 Nanotubes Act as an Immunomodulator and Delivery Vehicle for Norovirus Virus-Like Particles 2016 ·Journal of Immunology Research ·Maria Malm, Kirsi Tamminen, Suvi Lappalainen, Timo Vesikari, Vesna Blazevic	29
10	Rotavirus vaccination and infection induce VP6‐specific IgA responses 2016 ·Journal of Medical Virology ·Suvi Lappalainen, Vesna Blazevic, Maria Malm, Timo Vesikari	9
11	Mucosal Antibodies Induced by Intranasal but Not Intramuscular Immunization Block Norovirus GII.4 Virus-Like Particle Receptor Binding 2016 ·Viral Immunology ·Kirsi Tamminen, Maria Malm, Timo Vesikari, Vesna Blazevic	16
12	Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine in Children 6 Months to 17 Years of Age, Previously Vaccinated with an AS03-Adjuvanted A(H1N1)Pdm09 Vaccine 2015 ·The Pediatric Infectious Disease Journal ·Timo Vesikari, Jan Hendrik Richardus, Johan Berglund, Tiina Korhonen, Carl‐Erik Flodmark, Ann Lindstrand, Sven‐Arne Silfverdal, (unknown), Adrian Caplanusi, Ilse Dieussaert, Sumita Roy–Ghanta, David W. Vaughn	5
13	Detection of Vaccine-derived Rotavirus Strains in Nonimmunocompromised Children up to 3–6 Months After RotaTeq® Vaccination 2014 ·The Pediatric Infectious Disease Journal ·(unknown), Maria Hemming, Timo Vesikari	21
14	Efficacy, Immunogenicity, and Safety of Two Doses of a Tetravalent Rotavirus Vaccine RRV-TV in Ghana With the First Dose Administered During the Neonatal Period 2013 ·The Journal of Infectious Diseases ·George Armah, Albert Z. Kapikian, Timo Vesikari, Nigel A. Cunliffe, Robert M. Jacobson, D. Bruce Burlington, (unknown)	43
15	Serotype-Specific Efficacy of the Pentavalent Rotavirus Vaccine against Hospitalizations and Emergency Department Visits up to Three Years: The Finnish Extension Study 2008 ·46th Annual Meeting ·Timo Vesikari	2
16	RIX4414 ( Rotarix ™) is Highly Effective against Severe RVGE Caused by Specific Rotavirus Types during the First Two Years of Life. 2007 ·Timo Vesikari	1
17	Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries) 2007 ·International Journal of Infectious Diseases ·Timo Vesikari, Robbin Itzler, David O. Matson, Mathuram Santosham, C D C Christie, Michele L. Coia, J.R. Cook, Gary G. Koch, Penny M. Heaton	80
18	Evaluation of Live Attenuated Varicella Vaccine (Oka‐RIT Strain) and Combined Varicella and MMR Vaccination in 13–17‐Month‐Old Children 1991 ·Acta Paediatrica ·Timo Vesikari, (unknown), Maija Baer, A. Delem, H. Bogaerts, Francis André	21
19	Clinical efficacy of the RIT 4237 live attenuated bovine rotavirus vaccine in infants vaccinated before a rotavirus epidemic 1985 ·The Journal of Pediatrics ·Timo Vesikari, Erika Isolauri, A. Delem, (unknown), Francis André, G. M. Beards, T. H. Flewett	135
20	Evaluation of ELISA in the diagnosis of Yersinia enterocolitica diarrhoea in children. 1980 ·Apmis ·Timo Vesikari, Kaisa Granfors, Markku Mäki, P Grönroos	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact